Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-391 vs Co-administration in Healthy Volunteers
NCT03793985Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Sep 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-391 in hyperlipidemia (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to the last measurable concentration. Started Sep 2018; status: completed.
02
Drugs
CKD-391
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT03793985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03793985.